Psoriasis is a major immune-related global disease identified by the World Health Organization (WHO). In 2014, psoriasis was designated as "a serious non-infectious chronic disease" and called the "undead cancer". Nevertheless, there is a lack of safe and effective medicines for long-term use both at domestic and abroad.Though the causes and pathogenesis of psoriasis are not fully defined, the number of associated susceptibility genes is more than 80 currently. The incidence of psoriasis is increasing annually (global: >125 million; domestic: >8 million), with growing clinical evidences suggest that it is a disease with links to the human neurological and cardiovascular systems.The currently used topical, oral, injectable chemical and biological drugs are all symptomatic treatments. In recent years, new drugs developed for psoriasis treatment targeting TNF-α, IL and its receptors, PDE-4, T cells, etc. are expensive and have the risk of causing secondary infectionto patients. To achieve short-term clinical effects, the above-mentioned drugs have problems such as difficult to suppress relapses and high toxic side effects. In addition, the side effects caused by the use of chemical and biological drugs such as hormones and immunosuppressants for treatment may put patients with mild disease at risk of becoming moderate or severe, even life-threatening...numerous problems have been unresolved.In March 2016, the U.S. FDA, in its leading drug R&D program for patients with psoriasis, called on the pharmaceutical profession to develop safe, effective, long-term, and affordable drug therapy.The treatment guidelines for psoriasis emphasize the principle of "gentle therapy and combination of standardized and individualized treatment", ensuring firstly on patients' medication safety and life quality. Through strengthening health training for patients, including basic disease knowledge education, regular life guidance, dietary control, physical exercise, appropriate health care products and mental counseling, we can ultimately achieve the goals of controlling the disease, reducing recurrence and improving quality of life.The original new drug "TC" APIs and preparations are the world's first new natural plant-based small molecule drugs for psoriasis treatment, whose R&D ideas are derived from the long-term clinical application practices of the developers, which are extracting the effective part of a single traditional Chinese medicine, and using modern technology standards for R&D. TC ingredients are clear, quality controlled, safe and effective, which can be used for long-term. Pre-clinical studies have shown its anti-inflammatory, anti-allergic, anti-itching and regulating epidermal keratin-forming cell keratinization effects.Domestic and abroad clinical studies have proved its advantages of high cure rate, low side effects, low recurrence rate as well as its overall regulating effect on human immunity, which fully reflects natural botanical‘s therapeutic features compound with multi-target, multi-level and multi-system. These characteristics make them potentially become the irreplaceable or first-line guideline drugs in biology and chemistry compared to me-too copycat drugs.